Who owns Evolus, Inc. (EOLS)? Elite investor 13F holders
2 tracked elite investors reported holding Evolus, Inc as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | EVOLUS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2338093.00 USD | 336901.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | EVOLUS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2099829.00 USD | 302569.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.